Not provided
Not provided
Not provided
Not provided
Not provided
Due to recruitment difficulties
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates changes in Vitamin D, Zinc, and Iron status of children consuming 2 servings / day of the investigational (test) young children's milk (YCM) for 16 weeks compared to children of the same age who consume their habitual pattern of beverage intake for the same duration.
The overall purpose of the study is to demonstrate improved vitamin D status and/or improved iron status of children ages 1 to 3 years who are consuming the investigational (test) young children's milk (YCM) compared to children consuming their habitual pattern of beverage intake (milk and non-milk beverages). This is based on previous study findings that (i) the toddler's diet, in reality, is often not optimal, putting toddlers at risk of insufficient intakes of several nutrients, and (ii) consuming YCM supplemented with these nutrients might provide optimal intakes of these nutrients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| YCM Group (1- <3) Years old | Experimental | 2 servings / day of the investigational (test) young children's milk (YCM) for 16 weeks |
|
| Observation Group (1-<3) Years old | No Intervention | Habitual diet, consume the same regular foods and drinks as the children would normally |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Young children's milk (1-<3) | Other | young children's milk containing protein, energy and fat and micronutrients, in accordance with global and local nutritional recommendations for ages 1-3. |
| Measure | Description | Time Frame |
|---|---|---|
| change in Vitamin D and Iron status | measure blood vitamin D and Iron value | 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| change in Zinc status | measure blood Zinc value | 16 weeks |
| Assess micronutrient intake | Using 24 hour dietary recall | 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| assess other nutrient biomarkers | measure changes by blood measurement for CRP in mg/L | 16 weeks |
| assess other nutrient biomarkers | measure changes by blood measurement for serum retinol in μmol/L |
Inclusion Criteria:
Exclusion Criteria:
Child has consumed micronutrient supplements or micronutrient fortified foods or beverages in amounts greater than the thresholds below:
Chronic infectious illness, helminthiasis, or other acute disease/disorder potentially affecting feeding or growth (mild infectious illness, such as acute viral rhinopharyngitis, is acceptable).
Any congenital malformation (e.g., gastrointestinal tract atresia) or surgery sequelae (e.g. short bowel syndrome) potentially affecting feeding, growth, or nutrient absorption.
Child exhibits any clinical signs of potential micronutrient deficiencies (e.g., hemoglobin < 100 g/L based on screening assessment, rickets based on physical exam).
Known or suspected cows' milk protein intolerance / allergy, lactose intolerance, soy intolerance / allergy, fish oil intolerance / allergy, or other food allergies that affect diet.
Child fed vegan, vegetarian, or vegetarian plus fish diets in which milk products are excluded.
Weight-for-age value < -2 or > 2 standard deviations from the WHO(world health organization) Child Growth Standards median at enrollment.
Height-for-age < -2 or > 2 standard deviations from the WHO(world health organization) Child Growth Standards median at enrollment.
Child has participated in another clinical trial within 4 weeks prior to enrollment.
Child of any investigational site staff member or Nestle employee directly involved in the conduct of the trial.
Other medical or psychiatric condition that, in the judgement of the investigator, would make the child inappropriate for entry into the study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sudigdo Sastroasmoro, MD | Department of Child Health, Medical School, University of Indonesia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Indonesian Nutrition Association | Jakarta Pusat | Jakarta Special Capital Region | 10430 | Indonesia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 16 weeks |
| assess other nutrient biomarkers | measure changes by blood measurement for alpha(1)-acid glycoprotein in absolute value | 16 weeks |
| assess muscular fitness | measure changes by blood measurement for serum niacin | 16 weeks |
| assess muscular fitness | measure changes by blood measurement for plasma vitamin B6 | 16 weeks |
| assess child developmental milestones | measure Ages & Stages Questionnaires, Third Edition; Minimum 0, Maximum 60, higher scores indicate more positive outcomes | 16 weeks |
| assess child developmental milestones | measure Ages & Stages Questionnaires: Social-Emotional, Second Edition, Minimum 0, Maximum 180, lower scores indicate more positive outcomes | 16 weeks |
| assess bone mass index | measure the development of bone mass | 16 weeks |
| assess muscular fitness | measure handgrip strength using a portable dynamometer | 16 weeks |
| assess stool microbiota composition and metabolism and gut biomarkers | measure stool microbiota composition and metabolism, plus biomarkers of gut function (e.g., calprotectin, alpha-1 antitrypsin, albumin) and short-chain fatty acids. | 16 weeks |
| assess genetic markers of vitamin D metabolism / status | measure genetic variants isolated from blood draw | baseline |
| assess gastrointestinal (GI) tolerance | measure changes in gut comfort level min 10, max 60. Lower score indicate more positive outcomes | 16 weeks |
| assess YCM acceptability in children consuming GUM. | measure how well acceptable is YCM for interventional group, minimum score 5 max score 33. higher score indicate positive outcome | 16 weeks |
| To monitor growth and development | Anthropometry Assessment based on BMI in (kg/m^2) by weight (Kilograms), height (Metres) | 16 weeks |
| To monitor standard adverse events (AE) | safety assessment by monitoring the AEs linked with participation in study | 16 weeks |
| To monitor absenteeism from day care or pre-school due to illness | safety assessment by monitoring the days of absenteeism linked with participation in study | 16 weeks |
| To monitor concomitant medication (CM) reporting | safety assessment by monitoring the concomitant medication linked with participation in study | 16 weeks |